{"id":27367,"date":"2022-11-15T10:24:17","date_gmt":"2022-11-15T17:24:17","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/uncategorized\/guillain-barre-syndrome-vs-multiple-sclerosis-2\/"},"modified":"2025-06-03T09:37:48","modified_gmt":"2025-06-03T16:37:48","slug":"guillain-barre-syndrome-vs-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/","title":{"rendered":"S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple"},"content":{"rendered":"<p>El s\u00edndrome de Guillain-Barr\u00e9 (SGB) y la esclerosis m\u00faltiple (EM) son ambos <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/guide-to-demyelinating-disease\/\">enfermedades autoinmunes desmielinizantes<\/a>Aunque el s\u00edndrome de Guillain-Barr\u00e9 y la esclerosis m\u00faltiple son trastornos del sistema nervioso que duran toda la vida y tienen causas desconocidas, existen diferencias importantes entre ellos.<\/p>\n\n\n\n<p>El s\u00edndrome de Guillain-Barr\u00e9 y la esclerosis m\u00faltiple se pueden distinguir seg\u00fan los componentes que afectan a la enfermedad, los puntos de inicio y desencadenantes, los signos y s\u00edntomas, las poblaciones afectadas, los enfoques de tratamiento y m\u00e1s.<\/p>\n\n\n\n<p>En esta gu\u00eda, analizaremos m\u00e1s de cerca las diferencias entre el s\u00edndrome de Guillain-Barr\u00e9 y la esclerosis m\u00faltiple para que usted comprenda mejor ambas afecciones.<\/p>\n\n\n\n<div  id=\"call-to-action-5503fdc6d09ef84d463301c974690daf\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Disease-Targeted_Components\" >S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Componentes de la enfermedad<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Disease-Targeted_Components_in_GBS\" >Componentes del s\u00edndrome de Guillain-Barr\u00e9 dirigidos contra la enfermedad<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Disease-Targeted_Components_in_MS\" >Componentes dirigidos a la enfermedad en la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Affected_Population_and_Prevalence_Rate\" >S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Poblaci\u00f3n afectada y prevalencia<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Risk_of_GBS\" >Riesgo de SGB<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Risk_of_MS\" >Riesgo de EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Onset_and_Triggers_Points\" >S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Inicio y factores desencadenantes<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#The_Onset_and_Trigger_Points_of_GBS\" >El inicio y los puntos desencadenantes del s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#The_Onset_and_Trigger_Points_of_MS\" >El inicio y los puntos desencadenantes de la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Early_Signs_and_Symptoms\" >S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Signos y s\u00edntomas tempranos<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Symptoms_of_GBS\" >S\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Symptoms_of_MS\" >S\u00edntomas de la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Diagnostic_Approaches\" >S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Enfoques Diagn\u00f3sticos<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Diagnosis_of_GBS\" >Diagn\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Diagnosis_of_MS\" >Diagn\u00f3stico de la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Treatment_Options\" >S\u00edndrome de Guillain-Barr\u00e9 vs. esclerosis m\u00faltiple: opciones de tratamiento<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Treatments_for_GBS\" >Tratamientos para el s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Treatments_for_MS\" >Tratamientos para la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Prognosis_and_Long-term_Outlook\" >S\u00edndrome de Guillain-Barr\u00e9 vs. esclerosis m\u00faltiple: pron\u00f3stico y perspectivas a largo plazo<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Prognosis_for_GBS\" >Pron\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Prognosis_for_MS\" >Pron\u00f3stico de la EM<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#Manage_Multiple_Sclerosis_and_Guillain-Barre_Syndrome_With_AmeriPharma%C2%AE_Specialty_Pharmacy\" >Trate la esclerosis m\u00faltiple y el s\u00edndrome de Guillain-Barr\u00e9 con la farmacia especializada AmeriPharma\u00ae<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-disease-targeted-components\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Disease-Targeted_Components\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Componentes de la enfermedad<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Tanto en la EM como en el SGB, el sistema inmunol\u00f3gico, que funciona como defensa natural del cuerpo contra microorganismos da\u00f1inos como bacterias y virus, comienza a atacar de manera anormal <a href=\"https:\/\/www.brainfacts.org\/brain-anatomy-and-function\/anatomy\/2012\/the-neuron\" target=\"_blank\" rel=\"noreferrer noopener\">neuronas<\/a>, que son las c\u00e9lulas de comunicaci\u00f3n del sistema nervioso.<\/p>\n\n\n\n<p>En particular, el sistema inmunitario da\u00f1a o destruye la capa protectora llamada vaina de mielina, que rodea los axones de las neuronas. La vaina de mielina ayuda principalmente a la r\u00e1pida transmisi\u00f3n de se\u00f1ales del sistema nervioso al resto de los \u00f3rganos del cuerpo y viceversa.<\/p>\n\n\n\n<p>El da\u00f1o a la vaina de mielina interrumpe la comunicaci\u00f3n entre las neuronas y, en \u00faltima instancia, conduce a la p\u00e9rdida progresiva de todo tipo de funciones cognitivas, motoras y sensoriales.<\/p>\n\n\n\n<p>La esclerosis m\u00faltiple y el s\u00edndrome de Guillain-Barr\u00e9 parecen similares, pero existen diferencias notables que distinguen ambas afecciones y ayudan a los profesionales de la salud a utilizar enfoques de tratamiento diferentes en consecuencia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-disease-targeted-components-in-gbs\"><span class=\"ez-toc-section\" id=\"Disease-Targeted_Components_in_GBS\"><\/span>Componentes del s\u00edndrome de Guillain-Barr\u00e9 dirigidos contra la enfermedad<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"260\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves.jpg\" alt=\"Damaged nerve signals\" class=\"wp-image-27442\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves-300x186.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves-86x53.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves-167x103.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves-280x173.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-damaged-nerves-370x229.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>En el s\u00edndrome de Guillain-Barr\u00e9, el sistema inmunitario destruye la vaina de mielina del sistema nervioso perif\u00e9rico (una amplia gama de nervios fuera del cerebro y la m\u00e9dula espinal).<\/p>\n\n\n\n<p>La respuesta inmune a menudo se dirige a <a href=\"https:\/\/www.cambridge.org\/core\/books\/abs\/biology-of-schwann-cells\/guillainbarre-syndrome-and-the-schwann-cell\/C2658B8E06DE00F88BC1626DFF32A3EB\" target=\"_blank\" rel=\"noreferrer noopener\">c\u00e9lulas de Schwann<\/a>, que son importantes para la producci\u00f3n de mielina en estos nervios perif\u00e9ricos.<\/p>\n\n\n\n<p>Los nervios perif\u00e9ricos permiten que el cerebro se comunique con el resto de los \u00f3rganos del cuerpo, como el coraz\u00f3n, los pulmones, los ri\u00f1ones, los m\u00fasculos, etc.<\/p>\n\n\n\n<p>El da\u00f1o a estos nervios interrumpe la transmisi\u00f3n de se\u00f1ales, lo que provoca debilidad muscular, entumecimiento o, en la mayor\u00eda de los casos, <a href=\"https:\/\/www.emro.who.int\/cpi\/publications\/acute-flaccid-paralysis-risk-communication-and-community-engagement-guidance.html\" target=\"_blank\" rel=\"noreferrer noopener\">par\u00e1lisis fl\u00e1cida<\/a>Una de las diferencias entre el SGB y la EM es que el da\u00f1o a la mielina en el SGB generalmente es reversible.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-disease-targeted-components-in-ms\"><span class=\"ez-toc-section\" id=\"Disease-Targeted_Components_in_MS\"><\/span>Componentes dirigidos a la enfermedad en la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Por el contrario, en el caso de la esclerosis m\u00faltiple, el sistema inmunol\u00f3gico da\u00f1a la vaina de mielina del sistema nervioso central (cerebro y m\u00e9dula espinal) y las c\u00e9lulas que producen la vaina de mielina.<\/p>\n\n\n\n<p>El da\u00f1o a la mielina del sistema nervioso central a menudo se caracteriza por la formaci\u00f3n de placas escler\u00f3ticas, que interrumpen el flujo de impulsos el\u00e9ctricos entre el cerebro y el cuerpo.<\/p>\n\n\n\n<p>Este proceso puede provocar la degeneraci\u00f3n progresiva de las neuronas, lo que puede exacerbar s\u00edntomas como disfunci\u00f3n cognitiva, espasticidad y fatiga. Dado que el da\u00f1o nervioso es irreversible, provoca problemas de visi\u00f3n y discapacidad motora.<\/p>\n\n\n\n<div  id=\"call-to-action-93dcad1cab7ed4f03acf040c66df24a8\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga su dosis de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInfusi\u00f3n en casa\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Consulte a un especialista en IgIV<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-affected-population-and-prevalence-rate\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Affected_Population_and_Prevalence_Rate\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Poblaci\u00f3n afectada y prevalencia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Comprender la diferencia entre el SGB y la EM tambi\u00e9n es crucial para reconocer c\u00f3mo afectan a diferentes grupos demogr\u00e1ficos. Analicemos la prevalencia y los factores de riesgo asociados con cada afecci\u00f3n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-risk-of-gbs\"><span class=\"ez-toc-section\" id=\"Risk_of_GBS\"><\/span>Riesgo de SGB<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El SGB se presenta por igual en hombres y mujeres. Sin embargo, a medida que envejece, aumenta el riesgo de desarrollarlo. El SGB es poco com\u00fan y afecta solo a 1 de cada 100,000 personas al a\u00f1o, seg\u00fan... <a href=\"https:\/\/www.ninds.nih.gov\/guillain-barre-syndrome-fact-sheet\" target=\"_blank\" rel=\"noreferrer noopener\">Instituto Nacional de Trastornos Neurol\u00f3gicos y Accidentes Cerebrovasculares<\/a> informe.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-risk-of-ms\"><span class=\"ez-toc-section\" id=\"Risk_of_MS\"><\/span>Riesgo de EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El riesgo de desarrollar EM es tres veces mayor en la poblaci\u00f3n femenina que en la masculina, con una edad de inicio prevista entre los 20 y los 40 a\u00f1os. Aproximadamente <a href=\"https:\/\/n.neurology.org\/content\/86\/11\/1014.short\" target=\"_blank\" rel=\"noreferrer noopener\">2,5 millones de personas padecen EM en todo el mundo, mientras que en Estados Unidos se notifican 400.000 casos.<\/a>.<\/p>\n\n\n\n<div  id=\"call-to-action-a882bbbd21e0cb8363c8a26a5fdfcbae\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\t\u00bfPuede ayudar la IgIV?\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInformaci\u00f3n gratuita sobre el tratamiento con IgIV\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-onset-and-triggers-points\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Onset_and_Triggers_Points\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Inicio y factores desencadenantes<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Aunque tanto la esclerosis m\u00faltiple como el s\u00edndrome de Guillain-Barr\u00e9 son trastornos autoinmunes neurol\u00f3gicos, tienen diferentes puntos desencadenantes que pueden iniciar los s\u00edntomas y la progresi\u00f3n de la enfermedad.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-onset-and-trigger-points-of-gbs\"><span class=\"ez-toc-section\" id=\"The_Onset_and_Trigger_Points_of_GBS\"><\/span>El inicio y los puntos desencadenantes del s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El inicio de <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-symptoms\/\">S\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9<\/a> Se presenta principalmente precedida por infecciones bacterianas o virales. Algunos posibles desencadenantes <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/what-causes-guillain-barre-syndrome\/\">causas del s\u00edndrome de Guillain-Barr\u00e9<\/a> incluyen infecciones con pat\u00f3genos como <em>Campylobacter jejuni, Haemophilus influenzae, <\/em>citomegalovirus y SARS-Cov-2.<\/p>\n\n\n\n<p>Otros desencadenantes pueden incluir ciertas vacunas, el VIH o el SIDA, la enfermedad de Hodgkin o la cirug\u00eda.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-onset-and-trigger-points-of-ms\"><span class=\"ez-toc-section\" id=\"The_Onset_and_Trigger_Points_of_MS\"><\/span>El inicio y los puntos desencadenantes de la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Una diferencia notable entre el s\u00edndrome de Guillain-Barr\u00e9 y la esclerosis m\u00faltiple es que la esclerosis m\u00faltiple se desencadena por factores ambientales, que incluyen el tabaquismo, la deficiencia de vitamina D y la asociaci\u00f3n gen\u00e9tica.<\/p>\n\n\n\n<p>Aunque la esclerosis m\u00faltiple no se hereda directamente, es m\u00e1s probable que una persona desarrolle EM si tiene parientes biol\u00f3gicos con EM.<\/p>\n\n\n\n<p>En otras palabras, la esclerosis m\u00faltiple tiene un riesgo gen\u00e9tico que podr\u00eda heredarse. La heredabilidad... <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499849\/\" target=\"_blank\" rel=\"noreferrer noopener\">Se ha estimado que la frecuencia card\u00edaca de la esclerosis m\u00faltiple est\u00e1 entre 35% y 75%.<\/a>.<\/p>\n\n\n\n<p>Adem\u00e1s, algunas infecciones virales, como el virus de Epstein-Barr (VEB), el sarampi\u00f3n y el virus del herpes tipo 6, tambi\u00e9n pueden desencadenar la aparici\u00f3n de esclerosis m\u00faltiple. Estas infecciones causan inflamaci\u00f3n de la mielina.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-early-signs-and-symptoms\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Early_Signs_and_Symptoms\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Signos y s\u00edntomas tempranos<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"682\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2.jpg\" alt=\"A person sitting in a wheelchair comforted by a doctor\" class=\"wp-image-27487\" style=\"width:1170px;height:auto\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-768x512.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-600x400.jpg 600w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-280x186.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-370x246.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-wheelchair-doctor-1-1024x682-2-960x639.jpg 960w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Reconocer los primeros signos de la esclerosis m\u00faltiple y el s\u00edndrome de Guillain-Barr\u00e9 es esencial para una intervenci\u00f3n oportuna y un tratamiento eficaz. Si bien pueden compartir s\u00edntomas similares, cada afecci\u00f3n tiene caracter\u00edsticas distintivas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-symptoms-of-gbs\"><span class=\"ez-toc-section\" id=\"Symptoms_of_GBS\"><\/span>S\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Los signos m\u00e1s comunes y tempranos del SGB son debilidad muscular sim\u00e9trica y hormigueo en ambas piernas. Estas sensaciones comienzan en los pies y se extienden gradualmente a la parte superior del cuerpo. En el peor de los casos, causa par\u00e1lisis fl\u00e1cida.<\/p>\n\n\n\n<p>Otros s\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9 incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reflejos disminuidos<\/li>\n\n\n\n<li>Dificultad para respirar<\/li>\n\n\n\n<li>Dolor o molestias musculares<\/li>\n\n\n\n<li>Problemas de coordinaci\u00f3n<\/li>\n\n\n\n<li>Dificultad para caminar o correr<\/li>\n\n\n\n<li>Frecuencia card\u00edaca o presi\u00f3n arterial anormal<\/li>\n\n\n\n<li>Dificultad con el movimiento ocular, el movimiento facial, el habla o la degluci\u00f3n.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-symptoms-of-ms\"><span class=\"ez-toc-section\" id=\"Symptoms_of_MS\"><\/span>S\u00edntomas de la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Los s\u00edntomas de la EM suelen incluir visi\u00f3n borrosa o doble, problemas de movilidad, p\u00e9rdida del equilibrio, problemas del habla, alteraciones cognitivas y emocionales, fatiga, problemas intestinales, depresi\u00f3n y disfunciones sexuales.<\/p>\n\n\n\n<p>Estos s\u00edntomas suelen agravarse con el tiempo si no se detectan y tratan a tiempo. Sin atenci\u00f3n inmediata, las personas pueden enfrentar un mayor riesgo de complicaciones a largo plazo que afecten su calidad de vida y sus capacidades funcionales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-diagnostic-approaches\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Diagnostic_Approaches\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple: Enfoques Diagn\u00f3sticos<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Conocer las diferencias diagn\u00f3sticas entre el SGB y la EM es fundamental para una intervenci\u00f3n oportuna. Un diagn\u00f3stico preciso suele implicar una combinaci\u00f3n de evaluaciones cl\u00ednicas y pruebas especializadas adaptadas a cada afecci\u00f3n.<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-diagnosis-of-gbs\"><span class=\"ez-toc-section\" id=\"Diagnosis_of_GBS\"><\/span>Diagn\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/how-is-guillain-barre-syndrome-diagnosed\/\">Diagn\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<\/a> Se basa principalmente en los s\u00edntomas y un examen neurol\u00f3gico. Los profesionales de la salud tambi\u00e9n pueden emplear lo siguiente: <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/how-to-test-for-guillain-barre-syndrome\/\">pruebas de diagn\u00f3stico<\/a> Para confirmar la condici\u00f3n:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Punci\u00f3n lumbar (punci\u00f3n espinal):<\/strong> Esta prueba analiza el l\u00edquido cefalorraqu\u00eddeo (LCR) para detectar niveles elevados de prote\u00ednas con un recuento normal de gl\u00f3bulos blancos.<\/li>\n\n\n\n<li><strong>Estudios de conducci\u00f3n nerviosa (NCS):<\/strong> Esta prueba mide la rapidez con la que las se\u00f1ales el\u00e9ctricas viajan a trav\u00e9s de los nervios, lo que ayuda a identificar el da\u00f1o nervioso caracter\u00edstico del s\u00edndrome de Guillain-Barr\u00e9.<\/li>\n\n\n\n<li><strong>Electromiograf\u00eda (EMG):<\/strong> Esta prueba eval\u00faa la actividad el\u00e9ctrica de los m\u00fasculos, revelando anomal\u00edas en la respuesta muscular a la estimulaci\u00f3n nerviosa.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-diagnosis-of-ms\"><span class=\"ez-toc-section\" id=\"Diagnosis_of_MS\"><\/span>Diagn\u00f3stico de la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El diagn\u00f3stico de la esclerosis m\u00faltiple requiere una evaluaci\u00f3n integral que incluye una historia cl\u00ednica detallada y una exploraci\u00f3n neurol\u00f3gica. Diversas pruebas ayudan a identificar cambios espec\u00edficos de la EM en el sistema nervioso central, como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Im\u00e1genes por resonancia magn\u00e9tica (IRM):<\/strong> Esta t\u00e9cnica de im\u00e1genes detecta lesiones en el cerebro y la m\u00e9dula espinal, indicativas de EM.<\/li>\n\n\n\n<li><strong>Punci\u00f3n lumbar:<\/strong> De manera similar al s\u00edndrome de Guillain-Barr\u00e9, el an\u00e1lisis del LCR puede revelar bandas oligoclonales, un signo de un proceso inflamatorio en la EM.<\/li>\n\n\n\n<li><strong>Potenciales evocados (PE):<\/strong> Estas pruebas miden la actividad el\u00e9ctrica del cerebro en respuesta a est\u00edmulos, ayudando a detectar retrasos en la conducci\u00f3n nerviosa.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-treatment-options\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Treatment_Options\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. esclerosis m\u00faltiple: opciones de tratamiento<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>No existe cura para la esclerosis m\u00faltiple ni el s\u00edndrome de Guillain-Barr\u00e9. Sin embargo, existen opciones de tratamiento para controlar los s\u00edntomas de cada afecci\u00f3n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatments-for-gbs\"><span class=\"ez-toc-section\" id=\"Treatments_for_GBS\"><\/span>Tratamientos para el s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El manejo eficaz del SGB implica una combinaci\u00f3n de opciones de tratamiento adaptadas a la gravedad de la afecci\u00f3n. Estas intervenciones buscan reducir los s\u00edntomas y promover la cicatrizaci\u00f3n nerviosa.<\/p>\n\n\n\n<p>El principal <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-treatment-options\/\">Opciones de tratamiento para el s\u00edndrome de Guillain-Barr\u00e9<\/a> incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tratamiento con IgIV en dosis altas:<\/strong> <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/exploring-ivig-therapy-for-guillain-barre-syndrome\/\">Terapia con IgIV para el s\u00edndrome de Guillain-Barr\u00e9<\/a> Se utiliza para ayudar a modular la respuesta inmunitaria. La IgIV contiene anticuerpos que pueden ayudar a bloquear los efectos da\u00f1inos del sistema inmunitario sobre el sistema nervioso.<\/li>\n\n\n\n<li><strong>Intercambio de plasma:<\/strong> Tambi\u00e9n conocido como <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/plasmapheresis-for-guillain-barre-syndrome-benefits-risks-and-dose\/\">plasmaf\u00e9resis<\/a>Este procedimiento implica la extracci\u00f3n de plasma de la sangre y su reemplazo con una soluci\u00f3n sustituta para ayudar a reducir los ataques del sistema inmunol\u00f3gico al sistema nervioso.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatments-for-ms\"><span class=\"ez-toc-section\" id=\"Treatments_for_MS\"><\/span>Tratamientos para la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La esclerosis m\u00faltiple requiere un enfoque multifac\u00e9tico que busca controlar los s\u00edntomas y ralentizar la progresi\u00f3n de la enfermedad. El plan de tratamiento puede variar seg\u00fan el tipo de EM y los s\u00edntomas espec\u00edficos de cada paciente.<\/p>\n\n\n\n<p>Las principales opciones de tratamiento para la EM incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Medicamentos esteroides:<\/strong> Los corticosteroides, como la prednisona, reducen la inflamaci\u00f3n durante las reca\u00eddas de la EM. Estos medicamentos pueden ayudar a aliviar los s\u00edntomas y promover la recuperaci\u00f3n de los episodios agudos.<\/li>\n\n\n\n<li><strong>Terapias modificadoras de la enfermedad (TME):<\/strong> Estos medicamentos modifican la evoluci\u00f3n de la enfermedad y reducen la frecuencia y la gravedad de las reca\u00eddas. Entre los ejemplos de TME se incluyen el interfer\u00f3n beta y el acetato de glatir\u00e1mero. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/multiple-sclerosis\/gilenya-fingolimod-oral-disease-modifying-therapy-for-multiple-sclerosis-ms\/\">fingolimod<\/a>y fumarato de dimetilo.<\/li>\n\n\n\n<li><strong>Tratamientos sintom\u00e1ticos:<\/strong> Adem\u00e1s de los DMT, existen diversos medicamentos y terapias disponibles para controlar s\u00edntomas espec\u00edficos de la esclerosis m\u00faltiple, como espasticidad muscular, fatiga y disfunci\u00f3n de la vejiga.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guillain-barre-syndrome-vs-multiple-sclerosis-prognosis-and-long-term-outlook\"><span class=\"ez-toc-section\" id=\"Guillain-Barre_Syndrome_vs_Multiple_Sclerosis_Prognosis_and_Long-term_Outlook\"><\/span>S\u00edndrome de Guillain-Barr\u00e9 vs. esclerosis m\u00faltiple: pron\u00f3stico y perspectivas a largo plazo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"682\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1.jpg\" alt=\"An elderly woman seated in a garden\" class=\"wp-image-27444\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-768x512.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-600x400.jpg 600w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-280x186.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-370x246.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/guillain-barre-vs-multiple-sclerosis-woman-garden-1-1024x682-1-960x639.jpg 960w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Comprender el pron\u00f3stico y las perspectivas a largo plazo del SGB y la EM es crucial para los pacientes y sus familias. Ambas afecciones tienen trayectorias distintas que pueden afectar la calidad de vida.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prognosis-for-gbs\"><span class=\"ez-toc-section\" id=\"Prognosis_for_GBS\"><\/span>Pron\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-life-expectancy\/\">pron\u00f3stico del s\u00edndrome de Guillain-Barr\u00e9<\/a> En general, es favorable. Una diferencia clave entre el SGB y la EM es que la mayor\u00eda de los pacientes con SGB experimentan mejoras significativas en cuesti\u00f3n de semanas o meses despu\u00e9s del tratamiento.<\/p>\n\n\n\n<p>Hasta un 70% de personas se recuperan completamente, aunque algunas pueden tener efectos persistentes, como debilidad o problemas sensoriales.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prognosis-for-ms\"><span class=\"ez-toc-section\" id=\"Prognosis_for_MS\"><\/span>Pron\u00f3stico de la EM<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En cambio, la esclerosis m\u00faltiple es una enfermedad cr\u00f3nica con resultados variables a largo plazo. Si bien algunas personas pueden experimentar per\u00edodos de remisi\u00f3n, otras pueden experimentar un deterioro progresivo de su funci\u00f3n con el tiempo, lo que requiere tratamiento y atenci\u00f3n continuos.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manage-multiple-sclerosis-and-guillain-barre-syndrome-with-ameripharma-specialty-pharmacy\"><span class=\"ez-toc-section\" id=\"Manage_Multiple_Sclerosis_and_Guillain-Barre_Syndrome_With_AmeriPharma%C2%AE_Specialty_Pharmacy\"><\/span>Trate la esclerosis m\u00faltiple y el s\u00edndrome de Guillain-Barr\u00e9 con la farmacia especializada AmeriPharma\u00ae<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Comprender las diferencias entre el s\u00edndrome de Guillain-Barr\u00e9 y la esclerosis m\u00faltiple puede ayudarle a controlar mejor estas afecciones. Si padece EM o SGB y necesita tratamiento especializado, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/about-us\/\">Farmacia especializada AmeriPharma\u00ae<\/a> puede ayudar<\/p>\n\n\n\n<p>Nuestro acreditado ACHC <a href=\"https:\/\/ameripharmaspecialty.com\/es\/\">farmacia especializada<\/a> proporciona <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ig-home-infusion\/\">infusiones de IgIV en casa<\/a> y medicamentos dif\u00edciles de encontrar para personas con afecciones debilitantes en m\u00e1s de 40 estados y territorios de EE. UU.<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/get-started\/\">Cont\u00e1ctanos<\/a> Hoy para hablar con un especialista y recibir el tratamiento que necesita con una coordinaci\u00f3n de servicio completo, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/financial-assistance\/\">asistencia para copagos<\/a>y soporte 24\/7\/365.<\/p>","protected":false},"excerpt":{"rendered":"<p>El s\u00edndrome de Guillain-Barr\u00e9 (SGB) y la esclerosis m\u00faltiple (EM) son enfermedades autoinmunes desmielinizantes. Si bien el SGB y la EM son afecciones diferentes, tambi\u00e9n comparten algunas similitudes, y ambos son trastornos nerviosos cr\u00f3nicos y de por vida, de causas desconocidas.\u00a0<\/p>","protected":false},"author":26,"featured_media":27366,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[20,26],"tags":[32],"class_list":["post-27367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-guillain-barre-syndrome","category-multiple-sclerosis","tag-dr-robert-hakim"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guillain-Barre Syndrome vs. Multiple Sclerosis - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guillain-Barre Syndrome vs. Multiple Sclerosis - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Guillain-Barre syndrome (GBS) and multiple sclerosis (MS) are both demyelinating autoimmune diseases. Though GBS and MS are different conditions, they also share some similarities, and both are chronic and lifelong nervous disorders with unknown causes.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T17:24:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T16:37:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Robert Hakim, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Robert Hakim, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/\"},\"author\":{\"name\":\"Dr. Robert Hakim, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\"},\"headline\":\"Guillain-Barre Syndrome vs. Multiple Sclerosis\",\"datePublished\":\"2022-11-15T17:24:17+00:00\",\"dateModified\":\"2025-06-03T16:37:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/\"},\"wordCount\":1611,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg\",\"keywords\":[\"Dr. Robert Hakim\"],\"articleSection\":[\"Guillain-Barre Syndrome\",\"Multiple Sclerosis\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/\",\"name\":\"Guillain-Barre Syndrome vs. Multiple Sclerosis - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg\",\"datePublished\":\"2022-11-15T17:24:17+00:00\",\"dateModified\":\"2025-06-03T16:37:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg\",\"width\":1280,\"height\":853,\"caption\":\"A man holding his wrist in pain\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/guillain-barre-syndrome\\\/guillain-barre-syndrome-vs-multiple-sclerosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guillain-Barre Syndrome vs. Multiple Sclerosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\",\"name\":\"Dr. Robert Hakim, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"caption\":\"Dr. Robert Hakim, PharmD\"},\"description\":\"Dr. Robert Chad Hakim, PharmD, was born and raised in Northridge, CA. He received his pharmacy degree from the University of Wisconsin-Madison School of Pharmacy. The most rewarding part of his job is taking initiative to advance clinical programs that maximize impact on patient care. He has a board certification in critical care (BCCCP), and his areas of expertise are critical care, drug information, general medicine, and cardiology. In his free time, he enjoys traveling.\u00a0\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/robert-hakim\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple - AmeriPharma\u00ae Atenci\u00f3n Especializada","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_MX","og_type":"article","og_title":"Guillain-Barre Syndrome vs. Multiple Sclerosis - AmeriPharma\u00ae Specialty Care","og_description":"Guillain-Barre syndrome (GBS) and multiple sclerosis (MS) are both demyelinating autoimmune diseases. Though GBS and MS are different conditions, they also share some similarities, and both are chronic and lifelong nervous disorders with unknown causes.\u00a0","og_url":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2022-11-15T17:24:17+00:00","article_modified_time":"2025-06-03T16:37:48+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg","type":"image\/jpeg"}],"author":"Dr. Robert Hakim, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Robert Hakim, PharmD","Est. reading time":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/"},"author":{"name":"Dr. Robert Hakim, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759"},"headline":"Guillain-Barre Syndrome vs. Multiple Sclerosis","datePublished":"2022-11-15T17:24:17+00:00","dateModified":"2025-06-03T16:37:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/"},"wordCount":1611,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg","keywords":["Dr. Robert Hakim"],"articleSection":["Guillain-Barre Syndrome","Multiple Sclerosis"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/","url":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/","name":"S\u00edndrome de Guillain-Barr\u00e9 vs. Esclerosis M\u00faltiple - AmeriPharma\u00ae Atenci\u00f3n Especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg","datePublished":"2022-11-15T17:24:17+00:00","dateModified":"2025-06-03T16:37:48+00:00","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg","width":1280,"height":853,"caption":"A man holding his wrist in pain"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/guillain-barre-syndrome\/guillain-barre-syndrome-vs-multiple-sclerosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"Guillain-Barre Syndrome vs. Multiple Sclerosis"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/es\/#website","url":"https:\/\/ameripharmaspecialty.com\/es\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759","name":"Dr. Robert Hakim, Doctor en Farmacia","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","caption":"Dr. Robert Hakim, PharmD"},"description":"El Dr. Robert Chad Hakim, PharmD, naci\u00f3 y creci\u00f3 en Northridge, California. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Wisconsin-Madison. Lo m\u00e1s gratificante de su trabajo es tomar la iniciativa para impulsar programas cl\u00ednicos que maximicen el impacto en la atenci\u00f3n al paciente. Cuenta con una certificaci\u00f3n del consejo en cuidados cr\u00edticos (BCCCP) y sus \u00e1reas de especializaci\u00f3n son cuidados cr\u00edticos, informaci\u00f3n sobre medicamentos, medicina general y cardiolog\u00eda. En su tiempo libre, disfruta viajando.\u00a0","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"uagb_comment_info":0,"uagb_excerpt":"Guillain-Barre syndrome (GBS) and multiple sclerosis (MS) are both demyelinating autoimmune diseases. Though GBS and MS are different conditions, they also share some similarities, and both are chronic and lifelong nervous disorders with unknown causes.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/04\/guillain-barre-vs-multiple-sclerosis-man-wrist.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/guillain-barre-syndrome\/\" rel=\"category tag\">Guillain-Barre Syndrome<\/a> <a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/multiple-sclerosis\/\" rel=\"category tag\">Multiple Sclerosis<\/a>","rttpg_excerpt":"Guillain-Barre syndrome (GBS) and multiple sclerosis (MS) are both demyelinating autoimmune diseases. Though GBS and MS are different conditions, they also share some similarities, and both are chronic and lifelong nervous disorders with unknown causes.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27367"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27366"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27367"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}